University of Thessaly (UTH)
Το οξειδωτικό stress και ο αγγειακός ενδοθηλιακός αυξητικός παράγοντας στους ασθενείς με πρωτοπαθή καρκίνο πνεύμονα
Abstract
dc:descriptionOBJECTIVE: The aim of the present study was to determine Vascular endothelial growth factor (VEGF) and Oxidative stress (OS) levels, to investigate if there is any association between them and with other clinipathological factors and to assess the relevance of these levels to disease outcome. Materials and Methods: We measured serum OS and VEGF levels in 81 patients (age 62.48 ± 0.94 SEM) with primary lung cancer before any treatment (51 NSCLC; 9 patients stage I, 3 stage II, 16 stage III and 23 stage IV and 30 SCLC; 1 patients stage I, 2 stage II, 10 stage III and 17 stage IV) and in 25 normal subjects. The histological type of NSCLC was: 12/adenocarcinoma, 27/squamous cell carcinoma and 12 with no differentiated NSCLC. We also measured OS and VEGF levels after cisplatin based treatment in 43 of those 81 patients. The serum VEGF levels were measured with enzyme linked immunosorbent assay (ELIZA) and OS levels were detected by a commercially available assay (D-ROMs test, Diacron, Grossetto, Italy). Results: The serum levels of VEGF and OS were higher than those in normal subjects (p=0.0095 and p<0.0001, respectively). VEGF presented a significant correlation with OS levels before (p=0.0013, r=0.35) and after chemotherapy (p=0.025, r=0.34). There was no relevance of pretreatment serum VEGF and OS levels in response to therapy. Although, in the responders, after chemotherapy there was a significant decrement in serum VEGF leves (p=0.047) and a greater OS variation (p=0.03). Also, it was found a signifigant association between VEGF and OS levels and age of Lung cancer patients (p=0.004 and p=0.02, respectively). Nevertheless, there was no relevance with the others clinopathological factors. Patients with an OS serum level higher than the median serum level (552 UCarr) had a significantly shorter overall survival than those with a lower serum level (p=0.015, Log Rank Test). Also, shorter overall survival had patients with VEGF serum levels higher than the median (418pg/ml) serum level (p=0.048, Log Rank Test). Independent prognostic factors were found only VEGF and age of Lung cancer patients (p=0.0291and p=0.0423, respectively). Conclusions: High pre-treatment OS and VEGF levels may predict worse survival. Additionally, the correlation between these markers might implicate new aspects of lung cancer therapy and in conjunction with other clinical data, might be used for monitoring the patients with lung cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Κατσαμπέκη-Κατσαφλή, Αλεξάνδρα
- Katsabeki-Katsafli, Alexandra
Subjects
dc:subject × 20- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Οξειδωτικό στρες
- Αγγειογένεση
- Νεοπλασματική αγγειογένεση
- Καρκινογένεση
- Καρκίνος πνεύμονα
- Βιολογικοί δείκτες
- Προγνωστικοί δείκτες
- Vascular endothelial growth factor (VEGF)
- Oxidative stress
- Angiogenesis
- Neoangiogenesis
- Oncogenesis
- Lung cancer
- Biological markers
- Prognostic factors
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18189